CNMD
CONMED Corporation
CNMD has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has a slight edge over CNMD overall, supported by stronger fundamentals.
CNMD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Weak |
CNMD's profitability is currently healthy, and its revenue and cash flow are stable, but its balance sheet is weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CNMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 11x | $50.48 | — |
| Cheap | 17x | $41.30 | -18% |
| Current | 21x | $50.48 | — |
| Fair | 36x | $86.56 | +71% |
| Expensive | 76x | $185 | +266% |
Historical ranges are pointers, not guarantees.
CNMD's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 11x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over CNMD in the historical PE scenario, which offers more potential upside but is not a forecast.
CNMD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Stable | |
| Limited | |
| High |
Analysts expect CNMD's earnings to grow, with its revenue and profitability holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over CNMD on the outlook, with more favorable revenue and profitability expectations.
CNMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.63 | +91% |
| Q3 2026 | $2.42 | +17% |
| Q2 2026 | $1.85 | -48% |
| Q1 2026 | $1.77 | -54% |
| Q4 2025 | $1.51 | -64% |
| Q3 2025 | $2.06 | -51% |
| Q2 2025 | $3.54 | +13% |
| Q1 2025 | $3.81 | +46% |
| Q4 2024 | $4.25 | +108% |
CNMD's earnings per share have fallen from their peak: $2.42 over the past year, against $4.25 in late 2024.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
CNMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $335.6M | -0.7% |
| Q2 2026 | $343.5M | +0.3% |
| Q1 2026 | $317M | -1.3% |
| Q4 2025 | $373.2M | +7.9% |
| Q3 2025 | $337.9M | +6.7% |
| Q2 2025 | $342.3M | +3.1% |
| Q1 2025 | $321.3M | +2.9% |
| Q4 2024 | $345.9M | +5.8% |
CNMD's revenue grew through 2024 and has held roughly level since: $336M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 11% | +7.6 points |
| Q2 2026 | 11% | -0.6 points |
| Q1 2026 | 8% | +3 points |
| Q4 2025 | 9.8% | -5.4 points |
| Q3 2025 | 3.5% | -17 points |
| Q2 2025 | 11% | -3 points |
| Q1 2025 | 5% | -6.2 points |
| Q4 2024 | 15% | -0.2 points |
CNMD has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CNMD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
CNMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $46.7M | -3.7% |
| Q2 2026 | $34.2M | +46% |
| Q1 2026 | $10.6M | -72% |
| Q4 2025 | $41.2M | +4.9% |
| Q3 2025 | $48.5M | +1.5% |
| Q2 2025 | $23.4M | -41% |
| Q1 2025 | $37.8M | +39% |
| Q4 2024 | $39.3M | -24% |
CNMD generated $133M in free cash flow over the past year, down 11% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CNMD on cash flow, with more consistent year-over-year improvement.
CNMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +8K shares |
| 1 year | -3% | -925K shares |
| 3 years | -4.9% | -1.6M shares |
| 5 years | -6.3% | -2M shares |
| Available history | +2.1% | +630K shares |
CNMD has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6.2M |
| Q2 2026 | $6.2M |
| Q1 2026 | $37M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CNMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 4.3x | High |
| Q2 2026 | 5.2x | High |
| Q1 2026 | 5.3x | High |
| Q4 2025 | 5.1x | High |
| Q3 2025 | 4.8x | High |
| Q2 2025 | 3.8x | Elevated |
| Q1 2025 | 3.7x | Elevated |
| Q4 2024 | 3.5x | Elevated |
CNMD's net debt is about 4.3 years of its operating earnings (EBITDA), down from 4.8 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over CNMD on leverage, with a lower net debt burden relative to earnings.
CNMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.0 | Neutral |
| Stochastic | 49.0 | Neutral |
CNMD's weekly RSI is 59 (neutral) and its Stochastic is 49 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CNMD PE vs Healthcare Sector
| Metric | CNMD | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 26x | 19% below |
| PE % | 26 | 29 | 3 pts below |
CNMD is trading at 21x earnings, a 19% discount to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over CNMD on valuation relative to its sector.
CNMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $47.3 | 6.7% above |
| 20 week MA | $46.2 | 9.2% above |
| 50 week MA | $41.7 | 21% above |
| 100 week MA | $48.5 | 4.2% above |
| 200 week MA | $70.6 | 29% below |
CNMD has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 29% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CNMD on trend strength, trading above more of its moving averages.
CNMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $110.5 | $112.8 | +2.1% |
| 2021 | $112.8 | $142.0 | +26% |
| 2022 | $142.0 | $86.8 | -39% |
| 2023 | $86.8 | $109.5 | +26% |
| 2024 | $109.5 | $70.6 | -36% |
| 2025 | $70.6 | $40.8 | -42% |
| 2026 YTD | $40.8 | $50.5 | +24% |
CNMD has finished lower in three of the last six years. It's up 24% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CNMD on returns for 2026, with the stronger performance.